Ensysce Biosciences Inc
NASDAQ:ENSC

Watchlist Manager
Ensysce Biosciences Inc Logo
Ensysce Biosciences Inc
NASDAQ:ENSC
Watchlist
Price: 0.788 USD -6.97% Market Closed
Market Cap: $2.8m

Net Margin

-244.5%
Current
Improving
by 230.5%
vs 3-y average of -475%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-244.5%
=
Net Income
$-11m
/
Revenue
$4.5m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-244.5%
=
Net Income
$-11m
/
Revenue
$4.5m

Peer Comparison

Country Company Market Cap Net
Margin
US
Ensysce Biosciences Inc
NASDAQ:ENSC
2.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 89% of companies in the United States of America
Percentile
11th
Based on 15 072 companies
11th percentile
-244.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Ensysce Biosciences Inc
Glance View

Market Cap
2.8m USD
Industry
Biotechnology

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California. The company went IPO on 2017-12-01. The firm is engaged in the development of small and large molecule drug delivery platforms targeting pain and cancer markets. Ensysce’s products include PF614 and PF614- Multi-Pill Abuse Resistant (MPAR). PF614 is a Trypsin-Activated Abuse Protection (TAAP) oxycodone prodrug that is a biologically inactive compound which can be metabolized in the body to produce a drug with demonstrable features aimed at resisting both oral and non-oral modes of prescription drug abuse. TAAP technology seeks to remove the ability of a user to abuse PF614 intravenously or intra-nasally. PF614-MPAR is a combination product of PF614 and nafamostat has designed to limit abuse potential by providing resistance to use through injection or inhalation and to provide overdose protection against excessive oral ingestion. Ensysce initiated a Phase I clinical trial for PF614-MPAR to evaluate safety and Pharmacokinetics in healthy.

ENSC Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-244.5%
=
Net Income
$-11m
/
Revenue
$4.5m
What is Ensysce Biosciences Inc's current Net Margin?

The current Net Margin for Ensysce Biosciences Inc is -244.5%, which is above its 3-year median of -475%.

How has Net Margin changed over time?

Over the last 3 years, Ensysce Biosciences Inc’s Net Margin has increased from -1 113.9% to -244.5%. During this period, it reached a low of -1 113.9% on Sep 30, 2022 and a high of -88.8% on Jun 30, 2025.

Back to Top